Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70310-3 ◽

2013 ◽

Vol 14 (10) ◽

pp. 981-988 ◽

Cited By ~ 327

Author(s):

Marina Chiara Garassino ◽

Olga Martelli ◽

Massimo Broggini ◽

Gabriella Farina ◽

Silvio Veronese ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽

Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Current Oncology ◽

10.3747/co.23.2955 ◽

2016 ◽

Vol 23 (2) ◽

pp. 160 ◽

Cited By ~ 1

Author(s):

K.A. Ma ◽

G. Kasymjanova ◽

V. Cohen ◽

J. Agulnik

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung

Gemcitabine as single agent second line treatment in patients with advanced wild-type EGFR, negative ALK non-small cell lung cancer: a retrospective study

Annals of Oncology ◽

10.1093/annonc/mdw332.43 ◽

2016 ◽

Vol 27 ◽

pp. iv15

Author(s):

S. Rinaldi ◽

F. Morgese ◽

M. Torniai ◽

A. Savini ◽

F. Barbotti ◽

...

Keyword(s):

Lung Cancer ◽

Retrospective Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Single Agent ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung

Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial

Annals of Oncology ◽

10.1093/annonc/mdz122 ◽

2019 ◽

Vol 30 (7) ◽

pp. 1114-1120 ◽

Cited By ~ 13

Author(s):

R.Y. Tay ◽

F. Fernández-Gutiérrez ◽

V. Foy ◽

K. Burns ◽

J. Pierce ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Prognostic Value ◽

Controlled Trial ◽

Small Cell ◽

Circulating Tumour Cells ◽

Small Cell Lung ◽

Once Daily ◽

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial

BMC Surgery ◽

10.1186/s12893-018-0359-6 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 12

Author(s):

Jelle E. Bousema ◽

◽

Marcel G. W. Dijkgraaf ◽

Nicole E. Papen-Botterhuis ◽

Hermien W. Schreurs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Endoscopic Ultrasonography ◽

Study Protocol ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32517-x ◽

2017 ◽

Vol 389 (10066) ◽

pp. 255-265 ◽

Cited By ~ 1731

Author(s):

Achim Rittmeyer ◽

Fabrice Barlesi ◽

Daniel Waterkamp ◽

Keunchil Park ◽

Fortunato Ciardiello ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30013-9 ◽

2020 ◽

Vol 21 (4) ◽

pp. 581-592 ◽

Cited By ~ 14

Author(s):

Ursula Nestle ◽

Tanja Schimek-Jasch ◽

Stephanie Kremp ◽

Andrea Schaefer-Schuler ◽

Michael Mix ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Locally Advanced ◽

Target Volume ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(15)01281-7 ◽

2016 ◽

Vol 387 (10027) ◽

pp. 1540-1550 ◽

Cited By ~ 2708

Author(s):

Roy S Herbst ◽

Paul Baas ◽

Dong-Wan Kim ◽

Enriqueta Felip ◽

José L Pérez-Gracia ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Previously Treated ◽

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(06)70804-x ◽

2006 ◽

Vol 7 (9) ◽

pp. 719-727 ◽

Cited By ~ 934

Author(s):

Jean-Yves Douillard ◽

Rafael Rosell ◽

Mario De Lena ◽

Francesco Carpagnano ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Stage Ib ◽

Resected Stage ◽

Faculty Opinions recommendation of Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726044364.793539633 ◽

2017 ◽

Cited By ~ 2

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Previously Treated ◽